Avacta Group appoints Dr Sam Williams to its Board as Non-Executive Director

– UK, London – Avacta Group plc (LON:AVCT), the developer of Affimer biotherapeutics and reagents, today announced the appointment of Dr Sam Williams as Non-Executive Director to the Board with immediate effect.

Dr Eliot Forster, Chairman of Avacta Group, commented: “I am delighted that Dr Williams is joining Avacta and very much look forward to working with him. Sam has extensive experience of the Biotech industry both as an investor and operator which he will bring to the Board.”

About Dr Sam Williams

Dr Williams is currently Managing Partner and Head of Life Sciences at IP Group plc, the FTSE 250 investor in Life Sciences and Technology. He has an outstanding track-record in the biotech sector, both as a top-ranked biotechnology analyst in the City whilst at Lehman Brothers and, subsequently, as a Director and CEO, in which capacity he has overseen the development of novel therapeutics through early-stage clinical testing and successfully negotiated global alliances with major pharmaceutical companies. Thus, he brings extensive financial, operational and investment expertise to the Avacta Board.

Dr Williams was awarded a PhD in Molecular Biology by Cambridge University, earned while working in the laboratory of Sir Greg Winter, Nobel Laureate, and has a degree in Biology from Oxford University.

About Avacta Group plc

Avacta’s principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

For more information : https://www.avacta.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.